The ONL difference

ONL Therapeutics is pioneering an entirely new approach to preserving sight and halting vision loss associated with a range of retinal disease. The company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway.


ONL1204, the company’s lead therapeutic candidate is a first-in-class small peptide Fas inhibitor designed to protect the retina from cell death via both direct and inflammatory signaling in a range of retinal diseases.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search